de Pedro Cuesta J
Acta Neurol Scand Suppl. 1987;112:1-106.
The present study was motivated by the methodological issues revealed by a review of previous studies on Paralysis Agitans (PA) epidemiology. The study was given the following aims: To identify an easy available, inexpensive marker of PA frequency in populations; to develop, standardize and validate a model for measurement of PA prevalence by using that tracer; to study the geographical distribution of PA in Sweden, and to use the model in environmental risk analysis (ERA) for PA. Information on diagnoses and anti-parkinsonian drugs (APD) utilization from Swedish registers was analyzed, in order to select the group of APD which would best fulfill the prerequisites of specificity and preference of choice, and combined with prevalence data from direct surveys. Levodopa drugs were found to be the most suitable tracer for PA prevalence. A mathematical model was formulated to generate annual estimates for average age specific prevalences from total sales of levodopa, age specific population and figures for infant mortality rates. The following was required in order for the model to yield accurate estimates: high quality of the information to be used, good availability of levodopa drugs, a minimal size of the studied population of 100,000, an IMR lower than 28.8 per 1000 and that levodopa diffusion had reached the late adoption phase. Underdiagnosis was found to constitute an important cause of bias in classical surveys. Standardization for age and health services effectiveness by using infant mortality rates was shown to improve comparability of prevalence figures. The model was validated and showed internal consistency for age specific data on levodopa sales and on prevalence from Sweden and six Chinese towns, respectively. Estimates for prevalence for Iceland and Sardinia fitted historical data from direct surveys. The results of the ERA study showed that a high latitude and a low population density in 1900-20 were correlated with an increase in PA prevalence as measured by surveys or estimated by the use of the tracer method. Further analysis indicated that several so-called risk factors or concomitant diseases are associated with low population density. The geographical distribution of standardized PA prevalences in Swedish counties was studied for the period 1977-84. The findings were in accordance with the figures expected from the natural characteristics of the disease as determined by latitude and population density except in the county of Gävleborg which showed a significantly higher, and continuously increasing prevalence.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究的动机源于对帕金森病(PA)流行病学先前研究回顾所揭示的方法学问题。该研究设定了以下目标:确定一种在人群中易于获取且成本低廉的PA频率标志物;开发、标准化并验证一种使用该标志物测量PA患病率的模型;研究PA在瑞典的地理分布,并将该模型用于PA的环境风险分析(ERA)。分析了瑞典登记册中关于诊断和抗帕金森病药物(APD)使用的信息,以便选择最能满足特异性和选择偏好前提条件的APD组,并结合直接调查的患病率数据。发现左旋多巴药物是PA患病率最合适的标志物。构建了一个数学模型,根据左旋多巴的总销售额、特定年龄人口以及婴儿死亡率数据来生成特定年龄平均患病率的年度估计值。为使该模型产生准确估计值,需要满足以下条件:所使用信息的高质量、左旋多巴药物的良好可及性、研究人群最小规模为10万、婴儿死亡率低于每1000人28.8例,以及左旋多巴的传播已进入后期采用阶段。发现漏诊是经典调查中偏差的一个重要原因。通过使用婴儿死亡率对年龄和卫生服务效果进行标准化,可提高患病率数据的可比性。该模型经过验证,分别显示了瑞典和中国六个城镇关于左旋多巴销售的特定年龄数据以及患病率数据的内部一致性。冰岛和撒丁岛的患病率估计值与直接调查的历史数据相符。ERA研究结果表明,1900 - 20年期间的高纬度和低人口密度与通过调查测量或使用示踪法估计的PA患病率增加相关。进一步分析表明,一些所谓的风险因素或伴随疾病与低人口密度有关。研究了1977 - 1984年期间瑞典各县标准化PA患病率的地理分布。除了耶夫勒堡县显示出明显更高且持续上升的患病率外,研究结果与根据纬度和人口密度确定的疾病自然特征所预期的数字相符。(摘要截断于400字)